We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

The Hunt for the Neurofibromatosis Gene

Neil S. Goldberg, MD; Francis S. Collins, MD, PhD
Arch Dermatol. 1991;127(11):1705-1707. doi:10.1001/archderm.1991.01680100105014.
Text Size: A A A
Published online


• The neurofibromatosis type 1 (NF1) gene has been localized to the pericentromeric region of the long arm of chromosome 17. A chronology of events leading to the cloning of the NF1 gene is offered as a summary of modern gene hunting techniques. The gene was identified by its location rather than its function using positional cloning. Linkage analysis, based on DNA polymorphisms, is already available for prenatal and presymptomatic testing. This technique works only in cases when affected family members are available and is useless in spontaneous cases.

The complete NF1 gene is huge, has a large number of exons, and is approximately 240 000 base pairs long. Its large size is consistent with the very high spontaneous mutation rate. The NF1 gene is evolutionarily conserved and expressed ubiquitously, not just in neural crest derivatives. Functional and structural homology with GAP (GTP [guanosine triphosphate]ase—activating protein) has been described. The GAP controls (or is controlled by) the ras oncogene. Aberration of ras function, which plays a fundamental role in growth, development, and differentiation, may play a role in the NF1 phenotype.

Direct DNA diagnosis of mutations in the NF1 gene in clinical practice is premature. Current data suggest that the NF1 gene product may act as a tumor suppressor.

(Arch Dermatol. 1991;127:1705-1707)


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.